Postmarketing Surveillance Study of Erlotinib in Japanese Patients With Non–Small-Cell Lung Cancer (NSCLC): An Interim Analysis of 3488 Patients (POLARSTAR)
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 7 (8) , 1296-1303
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Current State of Drug-induced Lung Disease.Nihon Naika Gakkai Zasshi, 2011
- Erlotinib in Advanced Non-small Cell Lung Cancer: Efficacy and Safety Findings of the Global Phase IV Tarceva Lung Cancer Survival Treatment StudyJournal of Thoracic Oncology, 2010
- Efficacy and Safety of Erlotinib Monotherapy for Japanese Patients with Advanced Non-small Cell Lung Cancer: A Phase II StudyJournal of Thoracic Oncology, 2008
- Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritisModern Rheumatology, 2008
- Interstitial Lung Disease in Japanese Patients with Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumorsCancer Chemotherapy and Pharmacology, 2007
- Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitorsMedical Oncology, 2006
- Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylateLeukemia, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Reducing the risk of methotrexate pneumonitis in rheumatoid arthritisRheumatology, 2003